1.
Clin Infect Dis
; 32(12): e145-50, 2001 Jun 15.
Artículo
en Inglés
| MEDLINE
| ID: mdl-11360225
RESUMEN
We successfully treated 3 consecutive patients who had nonneutropenic rhinocerebral zygomycosis, by use of subcutaneous granulocyte-macrophage colony-stimulating factor therapy combined with traditional surgical and medical treatment. All patients are currently free of disease. Granulocyte-macrophage colony-stimulating factor should be considered as adjuvant therapy for rhinocerebral zygomycosis; however, optimum dose and length of therapy are unknown.